#1 Clinical Trials Search in Europe

Mps-112

This article summarizes several clinical trials investigating the use of MPS-112, also known as TEDOPI, for treating various types of cancer. TEDOPI is a cancer vaccine being studied as a potential new immunotherapy option for patients with advanced cancers like non-small cell lung cancer, ovarian cancer, and pancreatic cancer.

Table of Contents

What is MPS-112?

MPS-112 is one of the active ingredients in an experimental cancer vaccine called OSE2101 (also known as Tedopi)[1]. This vaccine is being developed as a potential new treatment for several types of cancer. It is considered a therapeutic cancer vaccine, which means it is designed to treat existing cancers rather than prevent them[2].

How Does MPS-112 Work?

OSE2101, which contains MPS-112, works by stimulating the body’s immune system to fight cancer cells. It is made up of 10 synthetically manufactured peptides (small protein fragments) that are designed to activate T cells, a type of immune cell that can recognize and attack cancer cells[3]. The vaccine is specifically designed for patients who have a certain protein on their cells called HLA-A2, which is present in about 45% of the population[1].

What Types of Cancer is MPS-112 Being Studied For?

MPS-112, as part of the OSE2101 vaccine, is currently being studied in clinical trials for several types of cancer:

  • Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer[1].
  • Ovarian Cancer: Specifically for patients with platinum-sensitive recurrent ovarian cancer[4].
  • Pancreatic Cancer: For patients with locally advanced or metastatic pancreatic ductal adenocarcinoma[3].

Current Clinical Trials

Several clinical trials are currently underway to test the effectiveness and safety of OSE2101 (containing MPS-112) for different types of cancer:

  • ARTEMIA Study: This is a phase 3 trial comparing OSE2101 to chemotherapy (docetaxel) in patients with advanced non-small cell lung cancer who have previously received immunotherapy[1].
  • TEDOVA Study: This is a phase 2 trial testing OSE2101 alone or in combination with another immunotherapy drug (pembrolizumab) for patients with recurrent ovarian cancer[4].
  • TEDOPAM Study: This is a phase 2 trial evaluating OSE2101 in combination with chemotherapy for patients with advanced pancreatic cancer[3].

Potential Benefits

The potential benefits of MPS-112 (as part of OSE2101) that researchers are investigating include:

  • Improved overall survival for cancer patients[1]
  • Better quality of life compared to standard chemotherapy[1]
  • Potential for longer-lasting responses to treatment[4]
  • Possibility of combining with other cancer treatments for enhanced effects[4][3]

Side Effects and Safety

As with any medical treatment, OSE2101 may cause side effects. The full range of potential side effects is still being studied in clinical trials. Some possible side effects may include:

  • Injection site reactions
  • Fatigue
  • Immune-related side effects

It’s important to note that the safety profile is still being evaluated in ongoing clinical trials[1][4][3].

Who May Be Eligible?

Eligibility for treatment with OSE2101 (containing MPS-112) varies depending on the specific clinical trial and type of cancer. However, some general criteria include:

  • Having HLA-A2 positive cancer cells (determined by a blood test)[1]
  • Having advanced or metastatic cancer that has not responded to or has progressed after standard treatments[1][4][3]
  • Being 18 years or older[1]
  • Having adequate organ function and overall health status[1][4][3]

Conclusion

MPS-112, as a component of the OSE2101 cancer vaccine, represents a promising new approach in cancer treatment. By harnessing the power of the immune system, it offers hope for patients with various types of advanced cancers. While the results of ongoing clinical trials are eagerly awaited, it’s important to remember that this treatment is still experimental. Patients interested in this treatment should discuss with their healthcare providers whether participating in a clinical trial might be appropriate for their individual situation.

Trial Name Cancer Type Phase Key Points
ARTEMIA Metastatic NSCLC III Comparing TEDOPI vs docetaxel in patients with secondary resistance to immunotherapy
OSE-279 Combination Advanced solid tumors, lymphomas, metastatic NSCLC I/II Evaluating TEDOPI in combination with OSE-279 (anti-PD-1 antibody)
TEDOVA Recurrent ovarian cancer II Testing TEDOPI alone or with pembrolizumab as maintenance therapy
TEDOPAM Advanced pancreatic cancer II Assessing TEDOPI plus FOLFIRI chemotherapy as maintenance after FOLFIRINOX

FAQ

  • What is MPS-112 (TEDOPI)? MPS-112 is one of the active substances in TEDOPI, which is an experimental cancer vaccine. It contains multiple synthetic peptides designed to stimulate the immune system to fight cancer cells.
  • What types of cancer is TEDOPI being studied for? TEDOPI is being investigated for treating advanced non-small cell lung cancer (NSCLC), recurrent ovarian cancer, and metastatic pancreatic cancer in these clinical trials.
  • How is TEDOPI administered? TEDOPI is given as a subcutaneous injection (an injection under the skin) in most of the trials described.
  • What are some of the main goals of these TEDOPI clinical trials? The main goals include assessing overall survival, progression-free survival, safety and tolerability, and tumor response rates in patients treated with TEDOPI alone or in combination with other therapies.
  • Who may be eligible to participate in these TEDOPI trials? Eligibility varies, but generally includes adult patients with advanced cancers who have a specific HLA-A2 genetic marker, adequate organ function, and meet other health criteria. Specific eligibility depends on the particular trial and cancer type being studied.

Ongoing Clinical Trials on Mps-112

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • HLA-A2: A specific genetic marker that is tested for in these trials to determine eligibility. It relates to how the immune system recognizes foreign substances.
  • NSCLC: Non-small cell lung cancer, a common type of lung cancer being studied in some of these trials.
  • Overall Survival (OS): The length of time from the start of treatment until death from any cause. This is an important measure of how well a cancer treatment works.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer getting worse.
  • RECIST: Response Evaluation Criteria in Solid Tumors. A standard way to measure how well a cancer patient responds to treatment.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.
  • Peptides: Short chains of amino acids. In TEDOPI, synthetic peptides are used to stimulate an immune response against cancer.
  • Subcutaneous injection: An injection given just under the skin.
  • Maintenance therapy: Treatment given to help keep cancer from coming back after it has responded to initial treatment.
  • Metastatic cancer: Cancer that has spread from where it started to other parts of the body.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/
  4. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/